Prostate Osteoblast-Like Cells: A Reliable Prognostic Marker of Bone Metastasis in Prostate Cancer Patients

The main aim of this study was to investigate the putative association among the presence of prostate cancer cells, defined as prostate osteoblast-like cells (POLCs), and showing the expression of typical morphological and molecular characteristics of osteoblasts, the development of bone metastasis within 5 years of diagnosis, and the uptake of 18F-choline evaluated by PET/CT analysis. To this end, prostate biopsies (n = 110) were collected comprising 44 benign lesions and 66 malignant lesions. Malignant lesions were further subdivided into two groups: biopsies from patients that had clinical evidence of bone metastasis (BM+, n = 23) and biopsies from patients that did not have clinical evidence of bone metastasis within 5 years (BM−, n = 43). Paraffin serial sections were obtained from each specimen to perform histological classifications and immunohistochemical (IHC) analysis. Small fragments of tissue were used to perform ultrastructural and microanalytical investigations. IHC demonstrated the expression of markers of epithelial-to-mesenchymal transition (VIM), bone mineralization, and osteoblastic differentiation (BMP-2, PTX-3, RUNX2, RANKL, and VDR) in prostate lesions characterized by the presence of calcium-phosphate microcalcifications and high metastatic potential. Ultrastructural studies revealed the presence of prostate cancer cells with osteoblast phenotype close to microcalcifications. Noteworthy, PET/CT analysis showed higher uptake of 18F-choline in BM+ lesions with high positivity (≥300/500 cells) for RUNX2 and/or RANKL immunostaining. Although these data require further investigations about the molecular mechanisms of POLCs generation and role in bone metastasis, our study can open new and interesting prospective in the management of prostate cancer patients. The presence of POLCs along with prostate microcalcifications may become negative prognostic markers of the occurrence of bone metastases.

[1]  M. Scimeca,et al.  PTX3: a new mediator of bone metabolism and osteoporosis , 2019, Muscle Ligaments and Tendons Journal.

[2]  E. Bonanno,et al.  Calcifications in prostate cancer: An active phenomenon mediated by epithelial cells with osteoblast‐phenotype , 2018, Microscopy research and technique.

[3]  N. Toschi,et al.  Radiological, Histological and Chemical Analysis of Breast Microcalcifications: Diagnostic Value and Biological Significance , 2018, Journal of Mammary Gland Biology and Neoplasia.

[4]  Orazio Schillaci,et al.  Management of oncological patients in the digital era: anatomic pathology and nuclear medicine teamwork. , 2018, Future oncology.

[5]  A. Mantovani,et al.  The Long Pentraxin 3 Plays a Role in Bone Turnover and Repair , 2018, Front. Immunol..

[6]  E. Bonanno,et al.  Energy Dispersive X-ray (EDX) microanalysis: A powerful tool in biomedical research and diagnosis , 2018, European journal of histochemistry : EJH.

[7]  S. Kojima,et al.  Present and Future Prospects of Radiation Therapy Using α-Emitting Nuclides , 2018, Dose-response : a publication of International Hormesis Society.

[8]  N. Toschi,et al.  Breast Osteoblast‐like Cells: A Reliable Early Marker for Bone Metastases From Breast Cancer , 2017, Clinical breast cancer.

[9]  M. Hofman,et al.  Prostate-specific membrane antigen theranostics: therapy with lutetium-177 , 2017, Current opinion in urology.

[10]  V. Tancredi,et al.  Impairment of PTX3 expression in osteoblasts: a key element for osteoporosis , 2017, Cell Death & Disease.

[11]  C. Cicciò,et al.  PET/CT with 18F-choline: Physiological whole bio-distribution in male and female subjects and diagnostic pitfalls on 1000 prostate cancer patients: 18F-choline PET/CT bio-distribution and pitfalls. A southern Italian experience. , 2017, Nuclear medicine and biology.

[12]  J. Stenvang,et al.  BMP-2 induces EMT and breast cancer stemness through Rb and CD44 , 2017, Cell Death Discovery.

[13]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2017, European urology.

[14]  S. Casimiro,et al.  Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside? , 2016, International journal of molecular sciences.

[15]  E. Bonanno,et al.  Emerging prognostic markers related to mesenchymal characteristics of poorly differentiated breast cancers , 2016, Tumor Biology.

[16]  J. Shendure,et al.  Substantial inter-individual and limited intra-individual genomic diversity among tumors from men with metastatic prostate cancer , 2016, Nature Medicine.

[17]  A. Pietroiusti,et al.  Elemental Analysis of Histological Specimens: A Method to Unmask Nano Asbestos Fibers , 2016, European journal of histochemistry : EJH.

[18]  J. Vadgama,et al.  Epithelial-Mesenchymal Transition and Breast Cancer , 2016, Journal of clinical medicine.

[19]  Jung Ha Kim,et al.  Signaling Pathways in Osteoclast Differentiation , 2016, Chonnam medical journal.

[20]  E. Bonanno,et al.  Breast Microcalcifications: A Focus , 2015 .

[21]  Jen-ming Huang,et al.  Prostate cancer metastasis: roles of recruitment and reprogramming, cell signal network and three-dimensional growth characteristics , 2015, Translational andrology and urology.

[22]  D. Rubello,et al.  The Optimal Timing to Perform 18F/11C-Choline PET/CT in Patients with Suspicion of Relapse of Prostate Cancer: Trigger PSA versus PSA Velocity and PSA Doubling Time , 2014, The International journal of biological markers.

[23]  E. Bonanno,et al.  Assessment of Metal Contaminants in Non-Small Cell Lung Cancer by EDX Microanalysis , 2014, European journal of histochemistry : EJH.

[24]  E. Bonanno,et al.  Microcalcifications in breast cancer: an active phenomenon mediated by epithelial cells with mesenchymal characteristics , 2014, BMC Cancer.

[25]  S. Dooley,et al.  Potential Roles of Bone Morphogenetic Protein (BMP)-9 in Human Liver Diseases , 2014, International journal of molecular sciences.

[26]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .

[27]  C. Garlanda,et al.  Pathogen Recognition by the Long Pentraxin PTX3 , 2011, Journal of biomedicine & biotechnology.

[28]  G. Djordjević,et al.  Role of bone morphogenetic proteins in human prostate cancer pathogenesis and development of bone metastases: immunohistochemical study. , 2010, Collegium antropologicum.

[29]  M. Rohde,et al.  Exocytotic Process as a Novel Model for Mineralization by Osteoblasts In Vitro and In Vivo Determined by Electron Microscopic Analysis , 2007, Calcified Tissue International.

[30]  Kozo Nakamura,et al.  Bone Morphogenetic Protein 2-Induced Osteoblast Differentiation Requires Smad-Mediated Down-Regulation of Cdk6 , 2004, Molecular and Cellular Biology.

[31]  T. Byzova,et al.  Molecular Pathway for Cancer Metastasis to Bone* , 2003, Journal of Biological Chemistry.

[32]  R. Coleman,et al.  Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment. , 2003, Cancer treatment reviews.

[33]  W. Isaacs,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Pathological and Molecular Aspects of Prostate Cancer Prostate Cancer Ii , 2022 .

[34]  T. Guise,et al.  Cancer and bone. , 1998, Endocrine reviews.

[35]  I. Fidler,et al.  The pathogenesis of cancer metastasis , 1980, Nature.

[36]  C. R. Howlett,et al.  The fine structure of the proximal growth plate of the avian tibia. , 1979, Journal of anatomy.

[37]  I. Fidler,et al.  Metastasis results from preexisting variant cells within a malignant tumor. , 1977, Science.

[38]  E. Bonanno,et al.  Osteoblast-like cells in human cancers: new cell type and reliable markers for bone metastasis. , 2018, Future oncology.

[39]  T. Komori.  Roles of Runx2 in Skeletal Development. , 2017, Advances in Experimental Medicine and Biology.

[40]  U. Tarantino,et al.  PTX3: a new mediator of bone metabolism and osteoporosis. , 2017, Muscles, ligaments and tendons journal.

[41]  C. Garlanda,et al.  Mesenchymal Stromal Cell-Derived PTX3 Promotes Wound Healing via Fibrin Remodeling. , 2016, The Journal of investigative dermatology.

[42]  W. Jiang,et al.  Cancer Invasion and Metastasis: Molecular and Cellular Perspective , 2013 .

[43]  T. Komori.  Regulation of osteoblast differentiation by Runx2. , 2010, Advances in experimental medicine and biology.

[44]  Wei Chen,et al.  Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis. , 2010, American journal of translational research.

[45]  K. Kelly,et al.  Mechanisms of cancer metastasis to the bone , 2005, Cell Research.

[46]  G Charette,et al.  Mineralization in osteoblast cultures: a light and electron microscopic study. , 1988, Bone.